GlaxoSmithKline (GSK) has unveiled six appointments to the board of Haleon, the new independent Consumer Healthcare company that will be formed following its planned demerger in July 2022.
Following the recent hiring of ex-Tesco CEO Sir Dave Lewis as Haleon’s Chairman, the board appointments include the transition of two GSK Non-Executive Directors – Vindi Banga and Dame Vivienne Cox – and three new external appointees.
The external hires include Tracy Clarke, a former Chief Executive at banking group Standard Chartered, and Deirdre Mahlan, the previous head of North American operations at Diageo. John Young is also joining from Pfizer, which owns around a third of the Consumer Healthcare business through a joint venture.
It was also confirmed that Tobias Hestler, CFO Designate for Haleon, will join Brian McNamara, CEO Designate, on the Board as an Executive Director.
Sir Dave commented: “We are delighted to be welcoming Vindi, Tracy, Vivienne, Deirdre and John as Non-Executive Directors to the future Board of Haleon. Together they bring considerable Board experience to support Haleon as a publicly listed company. They will also add in-depth understanding of the global consumer sector, with particular experience operating in the US, China, India and Europe. This is a significant step forward in creating the Haleon Board. We will look to add three more directors in due course.”
Having announced last month that the demerged company will be called Haleon, GSK outlined its strategy and outlook for the business at a Capital Markets Day for investors and analysts.
